| scholarly article | Q13442814 |
| P50 | author | Catherine M Greene | Q56915426 |
| Deirdre Fitzgerald-Hughes | Q57789080 | ||
| Marc C Devocelle | Q61827211 | ||
| Hilary Humphreys | Q64729399 | ||
| P2093 | author name string | Eanna Forde | |
| P2860 | cites work | Ancient antimicrobial peptides kill antibiotic-resistant pathogens: Australian mammals provide new options | Q21091000 |
| Antimicrobial peptides of multicellular organisms | Q28131811 | ||
| Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies | Q29617810 | ||
| High-throughput generation of small antibacterial peptides with improved activity | Q33220258 | ||
| Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis | Q33874056 | ||
| Novel synthetic, salt-resistant analogs of human beta-defensins 1 and 3 endowed with enhanced antimicrobial activity | Q33876601 | ||
| Antimicrobial peptide therapeutics for cystic fibrosis | Q33883742 | ||
| Bacterial host interactions in cystic fibrosis | Q34089951 | ||
| Magainins and the disruption of membrane-linked free-energy transduction | Q34300587 | ||
| Enhanced membrane pore formation through high-affinity targeted antimicrobial peptides | Q34328258 | ||
| Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme/meprin/epidermal growth factor receptor/Toll-like receptor pathway | Q34606483 | ||
| Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? | Q35010044 | ||
| Targeted killing of Streptococcus mutans by a pheromone-guided "smart" antimicrobial peptide | Q35127866 | ||
| Targeted antimicrobial activity of a specific IgG-SMAP28 conjugate against Porphyromonas gingivalis in a mixed culture | Q35203439 | ||
| A novel target-specific, salt-resistant antimicrobial peptide against the cariogenic pathogen Streptococcus mutans | Q35363615 | ||
| Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis | Q35557791 | ||
| Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens | Q37026697 | ||
| Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. | Q37072064 | ||
| Proteases and cystic fibrosis | Q37131650 | ||
| Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action | Q37377013 | ||
| Clinical challenges in addressing resistance to antimicrobial drugs in the twenty-first century | Q37538527 | ||
| Has the era of untreatable infections arrived? | Q37578902 | ||
| Designing antimicrobial peptides: form follows function. | Q37968899 | ||
| Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis | Q37991778 | ||
| Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives | Q37992706 | ||
| Current dilemmas in antimicrobial therapy in cystic fibrosis. | Q38042719 | ||
| Treatment of lung infection in patients with cystic fibrosis: current and future strategies | Q38058617 | ||
| Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials | Q38099053 | ||
| Human host defense peptide LL-37 prevents bacterial biofilm formation | Q38289682 | ||
| Chimeric beta-defensin analogs, including the novel 3NI analog, display salt-resistant antimicrobial activity and lack toxicity in human epithelial cell lines | Q39203205 | ||
| Biological properties of structurally related alpha-helical cationic antimicrobial peptides | Q39510622 | ||
| Antimicrobial activity of the recombinant designer host defence peptide P-novispirin G10 in infected full-thickness wounds of porcine skin. | Q40243759 | ||
| TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. | Q40468230 | ||
| Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. | Q40687738 | ||
| Targeted antimicrobial peptides. | Q41854349 | ||
| In vitro activities of synthetic host defense propeptides processed by neutrophil elastase against cystic fibrosis pathogens | Q42058965 | ||
| Salt resistance and synergistic effect with vancomycin of alpha-helical antimicrobial peptide P18. | Q43846571 | ||
| The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin | Q44296193 | ||
| Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis | Q44412993 | ||
| Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids | Q46875179 | ||
| Inhibition of neutrophil elastase in CF sputum by L-658,758. | Q48541764 | ||
| Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis | Q48563615 | ||
| Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane | Q50128217 | ||
| Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. | Q51084969 | ||
| Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. | Q52537084 | ||
| All-D-magainin: chirality, antimicrobial activity and proteolytic resistance. | Q54311933 | ||
| LL-37 Complexation with Glycosaminoglycans in Cystic Fibrosis Lungs Inhibits Antimicrobial Activity, Which Can Be Restored by Hypertonic Saline | Q58817684 | ||
| Targeting neutrophil elastase in cystic fibrosis | Q60056989 | ||
| Structure-antibacterial, antitumor and hemolytic activity relationships of cecropin A-magainin 2 and cecropin A-melittin hybrid peptides | Q77296547 | ||
| The antimicrobial peptide cathelicidin interacts with airway mucus | Q80236200 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 978-985 | |
| P577 | publication date | 2013-11-25 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Potential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis | |
| P478 | volume | 58 |
| Q35607838 | Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia. |
| Q27027316 | Antimicrobial peptides in 2014 |
| Q55263222 | Beta-defensin derived cationic antimicrobial peptides with potent killing activity against gram negative and gram positive bacteria. |
| Q33809988 | D-BMAP18 Antimicrobial Peptide Is Active In vitro, Resists to Pulmonary Proteases but Loses Its Activity in a Murine Model of Pseudomonas aeruginosa Lung Infection |
| Q27301457 | Delivery of a Protease-Activated Cytolytic Peptide Prodrug by Perfluorocarbon Nanoparticles |
| Q41289926 | Differential In Vitro and In Vivo Toxicities of Antimicrobial Peptide Prodrugs for Potential Use in Cystic Fibrosis. |
| Q38755670 | Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation |
| Q38814378 | Eradication of Staphylococcus aureus Biofilm Infections Using Synthetic Antimicrobial Peptides. |
| Q33673156 | Human antimicrobial peptides and proteins |
| Q33897664 | Mimicking the host and its microenvironment in vitro for studying mucosal infections by Pseudomonas aeruginosa |
| Q38369494 | Modifications of natural peptides for nanoparticle and drug design |
| Q28071357 | Neutrophil plasticity enables the development of pathological microenvironments: implications for cystic fibrosis airway disease |
| Q96303360 | Optimizing Exogenous Surfactant as a Pulmonary Delivery Vehicle for Chicken Cathelicidin-2 |
| Q35543287 | Pro-moieties of antimicrobial peptide prodrugs |
| Q64986513 | Vibrating Mesh Nebulisation of Pro-Antimicrobial Peptides for Use in Cystic Fibrosis. |
Search more.